Sanofi (NASDAQ:SNY) Upgraded at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi (NASDAQ:SNY) from a sell rating to a hold rating in a report issued on Thursday morning, Marketbeat.com reports.

Separately, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Trading Up 0.4 %

Shares of NASDAQ:SNY opened at $54.34 on Thursday. The stock has a 50 day moving average of $49.24 and a 200 day moving average of $52.28. The company has a market cap of $137.91 billion, a PE ratio of 27.72, a price-to-earnings-growth ratio of 1.21 and a beta of 0.57. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. As a group, equities research analysts expect that Sanofi will post 3.82 EPS for the current year.

Hedge Funds Weigh In On Sanofi

Hedge funds and other institutional investors have recently modified their holdings of the stock. Synergy Asset Management LLC purchased a new stake in Sanofi in the 4th quarter worth $25,000. McClarren Financial Advisors Inc. lifted its position in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares in the last quarter. Northwest Investment Counselors LLC bought a new position in Sanofi during the third quarter valued at approximately $29,000. Concord Wealth Partners grew its holdings in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares in the last quarter. Finally, Fortitude Family Office LLC increased its stake in Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.